Originally published as JCO Early Release 10.1200/JCO.2008.18.1370 on February 9 2009

This Article Full Text Full Text (PDF) Data Supplement Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Parker, J. S. Articles by Bernard, P. S. Search for Related Content PubMed PubMed Citation Articles by Parker, J. S. Articles by Bernard, P. S. Social Bookmarking                            What's this?

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

From the Lineberger Comprehensive Cancer Center and Departments of Genetics, Pathology and Laboratory Medicine, and Department of Statistics and Operations Research, Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC; Department of Pathology, University of Utah Health Sciences Center; ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT; Genetic Pathology Evaluation Centre, Department of Pathology, Vancouver Coastal Health Research Institute; Departments of Pathology and Radiation Oncology, British Columbia Cancer Agency; Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada; Genome Sequencing Facility and Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO; and Department of Pathology, Thomas Jefferson University, Philadelphia, PA.

Corresponding author: Philip S. Bernard, MD, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112-5550 e-mail: phil.bernard{at}hci.utah.edu.

Purpose To improve on current standards for breast cancer prognosis and prediction of chemotherapy benefit by developing a risk model that incorporates the gene expression–based "intrinsic" subtypes luminal A, luminal B, HER2-enriched, and basal-like.

Methods A 50-gene subtype predictor was developed using microarray and quantitative reverse transcriptase polymerase chain reaction data from 189 prototype samples. Test sets from 761 patients (no systemic therapy) were evaluated for prognosis, and 133 patients were evaluated for prediction of pathologic complete response (pCR) to a taxane and anthracycline regimen.

Results The intrinsic subtypes as discrete entities showed prognostic significance (P = 2.26E-12) and remained significant in multivariable analyses that incorporated standard parameters (estrogen receptor status, histologic grade, tumor size, and node status). A prognostic model for node-negative breast cancer was built using intrinsic subtype and clinical information. The C-index estimate for the combined model (subtype and tumor size) was a significant improvement on either the clinicopathologic model or subtype model alone. The intrinsic subtype model predicted neoadjuvant chemotherapy efficacy with a negative predictive value for pCR of 97%.

Conclusion Diagnosis by intrinsic subtype adds significant prognostic and predictive information to standard parameters for patients with breast cancer. The prognostic properties of the continuous risk score will be of value for the management of node-negative breast cancers. The subtypes and risk score can also be used to assess the likelihood of efficacy from neoadjuvant chemotherapy.

Supported by the Huntsman Cancer Institute/Foundation (P.S.B.), the ARUP Institute for Clinical and Experimental Pathology (P.S.B.), a National Cancer Institute (NCI) Strategic Partnering to Evaluate Cancer Signatures Grant No. U01 CA114722-01 (M.J.E.), an NCI Breast SPORE Grant No. P50-CA58223-09A1 (C.M.P.), a St Louis Affiliate of the Susan G. Komen Foundation CRAFT grant (M.J.E.), and the Breast Cancer Research Foundation (C.M.P. and M.J.E.). Additional support provided by the TRAC facility and Informatics at the Huntsman Cancer Center, supported in part by the NCI Cancer Center Support Grant No. P30 CA42014-19, and the tissue procurement facility at the Alvin J. Siteman Cancer Center at Washington University School of Medicine, which is funded in part by the NCI Cancer Center Support Grant No. P30 CA91842.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Koscielny Why Most Gene Expression Signatures of Tumors Have Not Been Useful in the Clinic Science Translational Medicine, January 13, 2010; 2(14): 14ps2 - 14ps2. [Full Text] [PDF]

				S. J. Howell, A. M. Wardley, and A. C. Armstrong Re: Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer J Natl Cancer Inst, December 16, 2009; 101(24): 1730 - 1730. [Full Text] [PDF]

				O. Gluz, C. Liedtke, N. Gottschalk, L. Pusztai, U. Nitz, and N. Harbeck Triple-negative breast cancer--current status and future directions Ann. Onc., December 1, 2009; 20(12): 1913 - 1927. [Abstract] [Full Text] [PDF]

				M. Cianfrocca and W. Gradishar New Molecular Classifications of Breast Cancer CA Cancer J Clin, September 1, 2009; 59(5): 303 - 313. [Abstract] [Full Text] [PDF]

				M. C. U. Cheang, S. K. Chia, D. Voduc, D. Gao, S. Leung, J. Snider, M. Watson, S. Davies, P. S. Bernard, J. S. Parker, et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer J Natl Cancer Inst, May 20, 2009; 101(10): 736 - 750. [Abstract] [Full Text] [PDF]

				R. J. Crowder, C. Phommaly, Y. Tao, J. Hoog, J. Luo, C. M. Perou, J. S. Parker, M. A. Miller, D. G. Huntsman, L. Lin, et al. PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer Cancer Res., May 1, 2009; 69(9): 3955 - 3962. [Abstract] [Full Text] [PDF]

				T. Sorlie Introducing Molecular Subtyping of Breast Cancer Into the Clinic? J. Clin. Oncol., March 10, 2009; 27(8): 1153 - 1154. [Full Text] [PDF]